Concord Biotech Q2 FY25 Results
Concord Biotech has released its financial results for the Q2 quarter of Financial Year 24-2025. Here's a comprehensive breakdown of the company's performance:
Revenue Analysis
- Current Quarter Revenue: Rs. 310.18 Cr
- Quarter-on-Quarter (QoQ) Change: 43.73% (Previous Quarter: Rs. 215.80 Cr )
- Year-on-Year (YoY) Change: 18.23% (Same Quarter Last Year: Rs. 262.35 Cr )
Profitability Metrics
- Net Profit: Rs. 95.74 Cr
- QoQ Profit Change: 60.66% (Previous Quarter: Rs. 59.59 Cr )
- YoY Profit Change: 18.17% (Same Quarter Last Year: Rs. 81.02 Cr )
Shareholder Returns
- Earnings Per Share (EPS): Rs. 9.15
- QoQ EPS Change: 60.53% (Previous Quarter: Rs. 5.70)
- YoY EPS Change: 18.22% (Same Quarter Last Year: Rs. 7.74)
Performance Summary
Strong
Concord Biotech performed strongly overall, but with some differences in growth areas. This shows they're adapting to market changes.
This analysis provides a snapshot of Concord Biotech's financial performance. Investors and analysts should consider these results in the context of broader market trends and the company's long-term strategy.
Disclaimer:
This information is for informational purposes only. Please reverify all details from official sources before making any financial decisions. The accuracy and completeness of this data cannot be guaranteed.